Afimkibart

(Synonyms: PF-06480605; RVT-3101)

Afimkibart (PF-06480605; RVT-3101) is a humanized monoclonal antibody targeting TL1A (TNFSF15). Afimkibart blocks the TL1A‑DR3 signaling axis by neutralizing the TL1A ligand, inhibits the release of pro-inflammatory cytokines, suppresses NF-κB activation and IFN-γ production, and simultaneously attenuates fibroblast activation and fibrosis progression associated with this pathway. The Fc region of Afimkibart contains the mutations L234A, L235A, and G237A, which are designed to reduce the binding of the antibody to FcγR and C1q, thereby attenuating or eliminating the antibody’s ADCC and CDC effector functions. Afimkibart is applicable to research on immune inflammation-related conditions, such as ulcerative colitis.

For research use only. We do not sell to patients.

  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biological Activity
  • Chemical Information
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00